Using skin fluid to diagnose and monitor heart diseases
Official title: Biomarkers in Dermal Interstitial Fluid for Early Diagnosis and Follow-up of Cardiovascular Diseases
Run by Ascilion AB · NCT06632353 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if skin fluid can help doctors find early signs of heart disease and monitor heart health in older adults with heart failure compared to younger people without heart issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Ascilion AB Industry-sponsored |
| Locations | 1 site (Danderyd) |
| Trial ID | NCT06632353 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals over 60 years with stable chronic heart failure or younger adults aged 18-40 without known heart or vascular diseases.
✕Probably not a fit
Patients with severe skin injuries, known heart or vascular diseases, or those who are pregnant or lactating may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study involves sampling dermal interstitial fluid (dISF) and blood plasma to investigate biomarkers that could aid in the early diagnosis and follow-up of cardiovascular diseases. Participants will be divided into two groups: one consisting of older adults with chronic heart failure and another of younger individuals without known heart conditions. The study aims to identify potential biomarkers in dISF that correlate with cardiovascular health. The methodology focuses on qualitative measurements to assess the effectiveness of these biomarkers.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of cardiovascular diseases, improving patient outcomes.
How similar studies have gone: While the use of biomarkers in blood plasma for cardiovascular diseases has been explored, the specific approach of using dISF is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: Group 1: Chronic heart failure with stable therapy. NYHA classification III and IV. Age \> 60 years. Group 2: Age 18-40 years. Exclusion criteria: * Participating in another clinical investigation which may affect the study outcome according to clinical judgement. * Previous use of sampling system used. * Pregnancy or lactating. * Any disease or condition that may be affected. * Individuals who lack the ability to fully consent to participate in the study. * Severe skin injury. * Tattoo or piercing close to sampling area. * Group 1: All forms of emergency care. * Group 1: Non-stable therapy. * Group 1: Sepsis. * Group 1: BMI \> 30kg/m2. * Group 1: Age \> 84 years. * Group 2: Known heart or vascular disease. * Group 2: Diabetes. * Group 2: Kidney disease.
Where it's running
-
Danderyd Hospital
Danderyd, Sweden Recruiting
Study contacts
- Study coordinator: Mikael Hillmering, PhD
- Email: mikael.hillmering@ascilion.com
- Phone: +46703018923
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery
This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients
This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.
-
One-stop photon-counting CT for patients after PCI
This study tests a single CT exam using photon-counting technology to image the heart after stent placement in people who have had PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.